TABLE 2.

Estimated amprenavir AUC_0–∞ for each Child-Pugh score and the proposed dosage required to achieve equivalence with the recommended 1,200-mg dose^a

Subject	Child-Pugh score	Estimated AUC0–∞ (ng · h/ml)b	AUC0–∞ ratio for healthy subjects:cirrhotic subjects	Recommended dose (mg) for equivalent exposure
Healthy subject	0	9,790	1.00	1,200
Hepatic failure, Child-Pugh score group A	5	26,125	0.37	450
	6	29,392	0.33	450
Hepatic failure, Child-Pugh score group B	7	32,659	0.30	450
	8	35,926	0.27	450
	9	39,193	0.25	300
Hepatic failure, Child-Pugh score group Cc	10	42,460	0.23	300
	11	45,727	0.21	300
	12	48,994	0.20	300
	13	52,261	0.19	300
	14	55,528	0.18	300
	15	58,795	0.17	300

^aProposed doses were rounded up to the nearest 150-mg dose to account for the amprenavir capsule strength. 

^bEstimated for the 600-mg dose used in this study by the linear model y = 3,267x + 9,790. See Results for details. 

^cNo subjects with a Child-Pugh score of >12 were enrolled; therefore, extrapolation of results to subjects with higher Child-Pugh scores should be made with caution.